rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nuvectis Pharma, Inc.

NVCT · Nasdaq

Health CareBiotechnologyLeading

NVCT stood above a rising 150-day average in 37 of the last 52 weekly readings, including each of the last 37 weeks. It is 17.2% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
37 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$3.5M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
83 (+23)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 37 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Ron BentsurChairman & CEObought12,500at $20.0030 Jun 2026filed 1 Jul 2026
Marlio Charles Mosseri10% ownerbought50,000at $18.3230 Jun 2026filed 1 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders83+23 on the quarter
New · exited32 · 8
Reported value$188.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TANG CAPITAL MANAGEMENT LLCnew · filed 14 Aug 20261,550,000$28.5M+1,550,000
BlackRock, Inc.added · filed 7 Aug 20261,001,285$18.4M+236,844+31.0%
PERCEPTIVE ADVISORS LLCnew · filed 14 Aug 20261,000,000$18.4M+1,000,000
Soleus Capital Management, L.P.new · filed 11 Aug 20261,000,000$18.4M+1,000,000
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026872,482$16.0M+212,603+32.2%
IRIDIAN ASSET MANAGEMENT LLCadded · filed 29 Jul 2026777,078$14.3M+125,321+19.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026432,273$8.0M+48,168+12.5%
SPHERA FUNDS MANAGEMENT LTD.new · filed 14 Aug 2026382,945$7.0M+382,945
BALDWIN WEALTH PARTNERS LLCadded · filed 14 Jul 2026382,015$7.0M+3,390+0.9%
Occam Crest Management LPreduced · filed 14 Aug 2026357,147$7.4M-50,000−12.3%
31 Mar 2023 – 30 Jun 2026
134780Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Michael J. Carson Company insiderVice President, Finance · last 3 Aug 20260 · 1
Marlio Charles Mosseri Company insider10% owner · last 30 Jun 202636 · 0
Ron Bentsur Company insiderChairman & CEO · last 30 Jun 202671 · 0
James F. Oliviero III Company insiderDirector · last 11 Jun 20260 · 0
Juan Sanchez Company insiderDirector · last 11 Jun 20261 · 0
Kenneth Hoberman Company insiderDirector · last 11 Jun 20261 · 0
Matthew L. Kaplan Company insiderDirector · last 11 Jun 20262 · 0
Enrique Poradosu Company insiderChief Science & Business Off · last 6 Jan 20266 · 0
Shay Shemesh Company insiderChief Dev. & Ops. Officer · last 6 Jan 202616 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-150%
Share count trendFY 2025 · to 6 Feb 20263.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$31.6M

Analyst forecasts

No analyst forecasts yet.